Skip to main content

Table 2 Genotype-phenotype association analysis for variants genotyped in stage 2 analysis

From: Addressing the contribution of previously described genetic and epidemiological risk factors associated with increased prostate cancer risk and aggressive disease within men from South Africa

Characteristic

PSA†(n = 462)

Family PCa†(n = 458)

Family Ca†(n = 451)

Age of PCa presentation¥(n = 265)

Gleason score¥(n = 180)

Grade¥(n = 147)

Marker (risk allele)

OR (95% CI)‡*

P§

Q¶

OR (95% CI)‡

P§

Q¶

OR (95% CI)‡

P§

Q¶

OR (95% CI)‡

P§

Q¶

OR (95% CI)‡

P§

Q¶

OR (95% CI)‡

P§

Q¶

rs6983561 (C)

1.35 (1.04-1.74)

0.02

0.40

1.40 (0.86-2.27)

0.18

0.60

0.91 (0.51-1.62)

0.75

0.84

0.81 (0.57-1.15)

0.24

0.68

1.11 (0.72-1.71)

0.63

0.81

1.73 (1.03-2.92)

0.04

0.35

rs1859962 (G)

1.28 (0.96-1.71)

0.09

0.60

1.00 (0.61-1.65)

0.99

0.99

0.58 (0.29-1.16)

0.12

0.60

0.95 (0.64-1.42)

0.82

0.86

1.22 (0.76-1.95)

0.42

0.76

1.84 (1.05-3.22)

0.03

0.35

rs13254738 (C)

1.15 (0.87-1.52)

0.33

0.60

1.04 (0.61-1.79)

0.88

0.93

1.12 (0.67-1.89)

0.66

0.79

1.06 (0.73-1.54)

0.75

0.86

0.72 (0.46-1.13)

0.15

0.68

1.16 (0.67-1.99)

0.60

0.81

rs10090154 (T)

0.89 (0.64-1.24)

0.50

0.75

0.70 (0.34-1.43)

0.33

0.60

1.44 (0.74-2.79)

0.29

0.60

1.03 (0.64-1.65)

0.91

0.91

0.79 (0.43-1.44)

0.43

0.76

1.28 (0.66-2.47)

0.47

0.76

rs4242382 (A)

0.81 (0.61-1.09)

0.17

0.60

0.87 (0.50-1.50)

0.62

0.79

1.20 (0.66-2.18)

0.54

0.75

1.06 (0.72-1.57)

0.78

0.86

1.21 (0.74-1.96)

0.45

0.76

1.46 (0.83-2.56)

0.19

0.68

rs1465618 (A)

1.29 (0.80-2.08)

0.29

0.60

1.46 (0.68-3.16)

0.33

0.60

1.43 (0.58-3.47)

0.44

0.71

0.71 (0.39-1.29)

0.26

0.68

1.54 (0.80-2.95)

0.20

0.68

1.30 (0.56-3.01)

0.54

0.81

  1. †Genotype-phenotype association analysis for PSA (< 20 μg/L = 0, ≥20 μg/L = 1), Family PCa (defined as first degree relatives affected by prostate cancer; no = 0, yes = 1) and Family Ca (defined as first and second degree relatives affected with any cancer; no = 0, yes = 1) was performed using all available samples (cases and controls).
  2. ¥Genotype-phenotype association analysis for Age of prostate cancer presentation (<70 yrs = 1, ≥70 yrs = 0), Gleason score (≤7 = 0, >7 = 1) and tumor Grade (well/moderate = 0, poor = 1) was performed on prostate cancer cases only.
  3. ‡OR (odds ratios) and 95% CI (confidence intervals) were estimated using unconditional logistic regression models.
  4. *PSA estimates were additionally controlled for Age.
  5. §Un-corrected P-values derived using logistic regression analysis.
  6. ¶Benjamini and Hochberg’s method to correct for false discovery rate [26] was used to generate Q-values.